UP!

A $100.37   View long term graphs

Agilent Technologies, Inc.
Type
Public
Traded as
  • NYSE: A
  • S&P 500 component
Industry
  • Healthcare equipment and services
Founded 1999 (spun off from HP)
Founder Bill Hewlett, David Packard (from HP)
Headquarters Santa Clara, California,
United States
Area served
Worldwide
Key people
  • Mike McMullen (CEO)
Products Instruments, software, services and consumables for laboratory use
Revenue IncreaseUS$4.2 billion (2016)
Operating income
IncreaseUS$615 million (2016)
Net income
IncreaseUS$462 million (2016)
Total assets IncreaseUS$7.8 billion (2016)
Total equity IncreaseUS$4.2 billion (2016)
Number of employees
13,500 (October 2017)
Divisions
  • Agilent CrossLab Group
  • Diagnostics & Genomics Group
  • Life Sciences & Applied Markets Group
Website www.agilent.com

Agilent Technologies is an American public research, development and manufacturing company established in 1999 as a spin-off from Hewlett-Packard. The resulting IPO of Agilent stock was the largest in the history of Silicon Valley at the time.

The company provides analytical instruments, software, services and consumables for the entire laboratory workflow. Agilent focuses its products and services on six markets: food, environmental and forensics, pharmaceutical, diagnostics, chemical and energy, and research. From 1999 to 2014 the company also produced test and measurement equipment for electronics, this division was spun out to form Keysight.

Based on 2003 information, Agilent maintained four locations in the San Francisco Bay area: San Jose, Santa Clara, Santa Rosa and Rohnert Park. Santa Clara is an R&D site, containing the Agilent Research Laboratories group. Based on 2006 information, Agilent maintained seven sites in China: an office in Beijing, and branches in Shanghai, Chengdu, Guangzhou, Shenyang, Shenzhen and Xi'an. Agilent also has several manufacturing facilities across Europe, most notably in Waldbronn Germany, Oxfordshire U.K. and Glostrup Denmark.

Agilent Technologies was created in 1999 by the spin-off of Hewlett-Packard's (HP's) "Medical Products and Instrument Group", including instrumentation and chemical analysis, electronic component and medical equipment product lines. The split was predicated on the difficulty of growing HP's revenue stream and on the competitive vigor of smaller, more agile competitors. The company's launch slogan was "Innovating the HP Way", which capitalized on the strong HP corporate culture. The starburst logo was selected to reflect "a burst of insight" (or "spark of insight") and the name "Agilent" aimed to invoke the notion of agility as a trait of the new firm. The Agilent spin-off was accompanied by an initial public offering which raised US$2,100,000,000, setting a record at the time.

In the early 2000s, "economic uncertainty" depressed demand for Agilent's products, including slow sales of health care products to hospitals in the United States, which accounted for 60% of the company's revenue at the time. The downturn also struck sales in the communications and semiconductor markets, where orders amounting to US$500,000,000 were canceled by buyers. These poor economic conditions prompted large reductions in force; from a headcount in 1999 of 35,000, which had risen to 48,000 by May 2001, it had by early 2003 cut 18,500 positions. In 2001, in midst of this downsizing, Agilent sold its health care and medical products organization to Philips Medical Systems, and was noted as having a valuation of about US$11,000,000,000. HP Medical Products had been the second oldest part of Hewlett-Packard, acquired in the 1950s.

In August 2005, Agilent announced the sale of its semiconductor business, which produced chips for a wide range of consumer and industrial uses, to Kohlberg Kravis Roberts and Silver Lake Partners for US$2,660,000,000. This move was part of a broad effort to concentrate "on the test-and-measurement business at its historic core," and would entail termination of about 1,300 of the company's 28,000 employees. The group operated as a private company, Avago Technologies, until August 2009, when it was brought public in an IPO. After purchasing Broadcom Corporation in 2016, Avago changed its name to Broadcom Limited.

Also in August 2005, Agilent sold its 47% stake in the light-emitting diode manufacturer Lumileds to Philips for US$1,000,000,000. Lumileds originally started as Hewlett-Packard's optoelectronics division.

Also in August 2005, Agilent announced a plan to divest its semiconductor test solutions business, composed of both the system-on-chip and memory test market areas. Agilent listed the new company as Verigy, mid-2006 on NASDAQ.

In 2009, Agilent announced the closure of a subsection of its Test & Measurement division. The product lines affected included the automated optical inspection, solder paste inspection, and automated X-ray products [5DX]. In 2004 Agilent reported that it had captured 19% of the US$244,000,000 (excluding Japan) global imaging inspection market. On July 27, 2009, Agilent announced they would buy Varian, Inc., for US$1,500,000,000. In November 2009, Agilent sold the N2X product line to IXIA. In February 2010 Agilent announced the selling of its Network Solutions Division to JDSU for US$162,000,000.

In 2011, the company along with the University of California, Davis, announced that it would be establishing the "Davis Millimeter Wave Research Center".

Agilent announced it would increase its life sciences engagement through the acquisition of Halo Genomics, based in Uppsala, Sweden, which was involved in next-generation sequencing technology development.

On May 17, 2012, Agilent agreed to buy Dako, a Danish cancer diagnostics company, for US$2,200,000,000, to expand its presence in the life sciences industry.

On Sept. 19, 2013, Agilent announced its decision to separate into two publicly traded companies: Agilent life sciences, diagnostics, applied markets company, and an electronic measurement company. The life sciences company will retain the Agilent name and the electronic measurement company will be called Keysight Technologies.

On Oct. 14 the company announced that it is exiting its Nuclear Magnetic Resonance business.

On Nov. 1 the formal separation of Agilent and Keysight Technologies was completed. Agilent announced it has completed the spin-off of its electronic measurement business, Keysight Technologies. Keysight begins trading on the New York Stock Exchange today under the symbol KEYS. The separation was implemented through a spinoff of Keysight’s common stock and is intended to be tax-free for U.S. federal income tax purposes. On Nov. 1, 2014, in a special dividend distribution of all outstanding shares of Keysight’s common stock, Agilent shareholders received one share of Keysight common stock for every two shares of Agilent common stock held as of close of business Oct. 22, 2014.

Agilent celebrates its 50th anniversary in the analytical instruments market. Hewlett-Packard Co., Agilent’s predecessor, acquired F&M Scientific Corp., maker of gas chromatographs, on Aug. 8, 1965. In September, the company announced it would acquire Seahorse Bioscience for $235 million.

On 7th of July Agilent announced that they had acquired U.K. based Cobalt Light Systems which develop and manufacture Raman spectroscopy instruments for £40 million in cash.

Agilent's inaugural president and chief executive officer was Ned Barnholt, and he retained this post at least through 2006. Barnholt had originally joined Hewlett-Packard in 1966.

In September 2014, William (Bill) Sullivan announced plans to retire as Agilent's CEO. Mike McMullen, then president of the company's Chemical Analysis Group, was to succeed Sullivan as CEO. As part of the succession plan announcement, McMullen was promoted to the roles of president and chief operating officer (COO).

In 2015, McMullen was elected by Agilent's board of directors to the post of CEO, becoming Agilent's third CEO.

As of 2017 Agilent Technologies are mainly held by institutional investors (T. Rowe Price, BlackRock, Fidelity Investments, The Vanguard Group, State Street Corporation, and others)

News

Agilent Technologies, Inc. 0.96% (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q1 2021 2021-02-16 Future report Set alerts
Q4 2020 2020-11-23 Future report Set alerts
Q3 2020 2020-08-18 0.78 0.64
Q2 2020 2020-05-21 0.71 0.32
Q1 2020 2020-02-18 0.81 0.63
Q4 2019 2019-11-25 0.89 0.62
Q3 2019 2019-08-14 0.76 0.60
Q2 2019 2019-05-14 0.71 0.57
Q1 2019 2019-02-20 0.76 1.57
Q4 2018 2018-11-19 0.81 0.61

Ratings

2016-06-30 Reiterated Rating Leerink Swann Outperform $51.00
2016-06-08 Reiterated Rating Barclays Hold $45.00
2016-06-08 Reiterated Rating Barclays PLC Hold $45.00
2016-06-01 Initiated Coverage Deutsche Bank Hold
2016-06-01 Initiated Coverage Deutsche Bank AG Hold
2016-05-29 Reiterated Rating BTIG Research Buy $50.00
2016-05-26 Reiterated Rating Cowen and Company Outperform $47.00 to $49.00
2016-05-26 Reiterated Rating Leerink Swann Buy
2016-05-17 Upgrade BTIG Research Buy $50.00
2016-05-17 Reiterated Rating Morgan Stanley Hold $44.00 to $47.00
2016-05-17 Reiterated Rating Wells Fargo Hold $43.50 to $44.50
2016-05-17 Reiterated Rating Leerink Swann Buy $44.00 to $51.00
2016-05-17 Reiterated Rating Evercore ISI Buy $43.00 to $48.00
2016-05-17 Boost Price Target Barclays Equal Weight $42.00 to $45.00
2016-05-17 Reiterated Rating Jefferies Group Buy $46.00 to $51.00
2016-05-17 Reiterated Rating Wells Fargo & Co. Hold $43.50 to $44.50
2016-05-11 Upgrade Goldman Sachs Buy to Conviction-Buy $47.00 to $49.00
2016-05-11 Upgrade Goldman Sachs Group Inc. Buy to Conviction-Buy $47.00 to $49.00
2016-03-23 Boost Price Target Goldman Sachs $47.00
2016-03-08 Reiterated Rating Leerink Swann Buy
2016-03-08 Reiterated Rating BTIG Research Buy $50.00
2016-02-17 Lower Price Target Goldman Sachs Buy $46.00 to $45.00
2016-02-17 Lower Price Target Evercore ISI Buy $46.50 to $42.00
2016-02-17 Reiterated Rating Deutsche Bank Neutral to Hold $42.00 to $39.00
2016-02-17 Lower Price Target Cowen and Company Outperform $46.00 to $44.00
2016-02-17 Lower Price Target Barclays Equal Weight $44.00 to $42.00
2016-02-17 Reiterated Rating Bank of America Equal Weight $44.00 to $42.00
2016-02-17 Reiterated Rating Robert W. Baird Outperform $48.00 to $46.00
2016-02-17 Reiterated Rating BTIG Research Buy $50.00
2016-02-17 Reiterated Rating Bank of America Corp. Equal Weight $44.00 to $42.00
2016-01-07 Boost Price Target Barclays Equal Weight $41.00 to $44.00
2016-01-06 Initiated Coverage Deutsche Bank Hold $42.00
2015-12-09 Upgrade Robert W. Baird Neutral to Outperform $45.00 to $48.00
2015-12-08 Upgrade Goldman Sachs Neutral to Buy $9.00 to $48.00
2015-11-17 Reiterated Rating Cowen and Company Hold
2015-11-17 Lower Price Target Jefferies Group Buy $48.00 to $46.00
2015-11-17 Boost Price Target Evercore ISI Buy $39.00 to $42.50
2015-11-17 Lower Price Target Barclays Equal Weight $44.00 to $41.00
2015-11-17 Reiterated Rating Leerink Swann Outperform $47.00 to $44.00
2015-11-13 Lower Price Target BTIG Research Buy $52.00 to $50.00
2015-10-15 Lower Price Target Citigroup Inc. Neutral $42.00 to $40.00
2015-10-02 Lower Price Target Cowen and Company $42.00 to $39.00
2015-09-30 Reiterated Rating Jefferies Group Buy $48.00
2015-08-18 Reiterated Rating Leerink Swann Outperform $47.00
2015-08-14 Reiterated Rating BTIG Research Buy $52.00
2015-05-29 Boost Price Target Jefferies Group Buy $47.00 to $48.00
2015-05-20 Reiterated Rating Morgan Stanley Equal Weight $47.00
2015-05-20 Reiterated Rating Jefferies Group Buy $47.00
2015-05-19 Reiterated Rating BTIG Research Buy $52.00
2015-05-19 Boost Price Target Robert W. Baird Neutral $42.00 to $45.00
2015-02-25 Upgrade BTIG Research Neutral to Buy $52.00
2015-01-07 Boost Price Target Citigroup Inc. Neutral $40.00 to $42.00
2015-01-07 Initiated Coverage Barclays Equal Weight
2014-11-18 Lower Price Target JPMorgan Chase & Co. Overweight $65.00 to $45.00
2014-11-18 Downgrade Cowen and Company Outperform to Market Perform $63.00 to $42.00
2014-11-04 Reiterated Rating Citigroup Inc. Neutral $45.77 to $40.00
2014-11-04 Reiterated Rating Bank of America Buy $59.00 to $45.00
2014-11-04 Downgrade Robert W. Baird Outperform to Neutral $59.00 to $42.00
2014-11-04 Downgrade Wells Fargo & Co. Outperform to Market Perform $40.84
2014-11-04 Downgrade Wells Fargo Outperform to Market Perform $40.84
2014-10-29 Reiterated Rating Morgan Stanley Equal Weight $53.00 to $55.00
2014-10-20 Reiterated Rating Bank of America Buy $64.00 to $59.00
2014-10-14 Reiterated Rating Morgan Stanley Equal Weight $62.00 to $59.00
2014-10-03 Initiated Coverage ING Group Neutral
2014-10-02 Initiated Coverage BTIG Research Neutral
2014-09-08 Initiated Coverage Morgan Stanley Equal Weight $62.00
2014-07-17 Initiated Coverage Citigroup Inc. Neutral
2014-06-23 Initiated Coverage Goldman Sachs Neutral
2014-05-15 Reiterated Rating Bank of America Buy $65.00 to $64.00
2014-05-12 Reiterated Rating Jefferies Group Buy $67.00 to $66.00
2014-02-18 Upgrade Ned Davis Research Neutral to Buy
2014-02-12 Boost Price Target Leerink Swann Outperform $59.00 to $68.00
2014-01-10 Reiterated UBS Buy $57 to $65
2014-01-06 Reiterated Rating Morgan Stanley Overweight $60.00 to $65.00
2013-12-18 Boost Price Target Cowen and Company $57.00 to $65.00
2013-12-17 Boost Price Target Jefferies Group $60.00 to $65.00
2013-11-15 Boost Price Target Evercore ISI Strong-Buy $63.00
2013-11-15 Reiterated Rating Citigroup Inc. Buy $53.00 to $59.00
2013-10-01 Downgrade Stifel Buy to Hold
2013-10-01 Downgrade Stifel Nicolaus Buy to Hold $52.00
2013-09-20 Reiterated UBS Buy $50 to $57
2013-09-20 Boost Price Target Barclays Overweight $52.00 to $58.00
2013-09-20 Reiterated Rating Morgan Stanley Overweight $49.00 to $60.00
2013-09-20 Reiterated Rating Jefferies Group Buy $54.00 to $60.00
2013-09-19 Upgrade ISI Group Buy to Strong Buy $56 to $63.50
2013-09-19 Upgrade Evercore ISI Buy to Strong-Buy $56.00 to $63.50
2013-09-19 Upgrade Janney Montgomery Scott Neutral to Buy $50.00 to $66.00
2013-08-15 Reiterated Stifel Buy $48 to $52
2013-08-15 Reiterated ISI Group Buy $49.50 to $53.50
2013-08-15 Reiterated Barclays Equal Weight $45 to $52
2013-05-15 Reiterated Stifel Buy $46 to $48
2013-05-15 Reiterated ISI Group Buy $47 to $50
2013-02-15 Reiterated Barclays Overweight $48 to $45
2013-02-12 Reiterated UBS Buy $46 to $51
2013-01-28 Reiterated Barclays Overweight $43 to $48
2012-12-17 Reiterated Barclays Overweight $40 to $43
2012-01-13 Reiterated Longbow Buy $44 to $50
2011-11-16 Reiterated Barclays Capital Overweight $44 to $48
2011-10-24 Initiated UBS Buy $43
2011-10-17 Reiterated Barclays Capital Overweight $49 to $44
2011-10-13 Reiterated Longbow Buy $56 to $44
2011-08-16 Reiterated Stifel Nicolaus Buy $59 to $50
2016-06-30 Reiterated Rating Leerink Swann Outperform $51.00
2016-06-08 Reiterated Rating Barclays Hold $45.00
2016-06-08 Reiterated Rating Barclays PLC Hold $45.00
2016-06-01 Initiated Coverage Deutsche Bank Hold
2016-06-01 Initiated Coverage Deutsche Bank AG Hold

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
SULLIVAN WILLIAM P CEO 0.14%  (458166) A / AVT / EIX / MXIM / URS /
McMullen Michael R. Senior Vice President 0.10%  (324686) A /
HIRSCH DIDIER Sr. VP and CFO 0.06%  (184431) A / IRF / KN / LOGI /
Nersesian Ronald S. President and COO 0.03%  (102821) A / TRMB /
CLARK PAUL N 0.03%  (90929) A / BIOL /
Roelofs Nicolas H PHD Senior Vice President 0.03%  (84136) A /
RAND A BARRY 0.02%  (79308) A / CPB /
CULLEN JAMES 0.02%  (76472) A / JNJ / NSR / PRU /
HERBOLD ROBERT J 0.02%  (75937) A /
KOH BOON HWEE 0.02%  (75063) A / BVSN /
HALLORAN JEAN Senior Vice President 0.02%  (74961) A /
Kaltenbach Patrick Sr Vice President 0.02%  (68547) A /
Doak Mark Sr. Vice President 0.02%  (65533) A /
Grau Dominique Senior Vice President 0.02%  (60699) A /
FIELDS HEIDI 0.02%  (52562) A / FNGN /
Yamada Tadataka 0.01%  (48647) A /
Huber Marie Oh Sr VP, General Counsel & Sec. 0.01%  (44771) A / EBAY /
Thaysen Jacob Sr Vice President 0.01%  (40459) A /
LAWRENCE DAVID M 0.01%  (39202) A / MCK /
Ancher-Jensen Henrik Sr Vice President 0.01%  (39023) A /
Tang Michael SVP, General Counsel, and Sec. 0.01%  (33539) A /
Sene Guy Senior Vice President 0.01%  (32713) A /
Strohmeier Fred Senior Vice President 0.01%  (27496) A /
Gonsalves Rodney V.P., Corporate Controller 0.01%  (24424) A /
SCANGOS GEORGE A 0.01%  (19573) A / BIIB / EXEL /
Podolsky Daniel K 0.01%  (18407) A /

Comments